Histopathologic survey on lung necropsy specimens of 15 patients who died from COVID-19: A large study from Iran with a high rate of anthracosis

Abstract

A critical point for better management of COVID-19 is: knowing more about exact pathomechanisms of events in different organs during disease course and COVID-related histopathological events like tissue sampling, either biopsy or necropsy/autopsy of died people, collecting from different populations. →What this article adds:In lung necropsy of 15 Iranian patients, we found similar presentation of histopathologic events compared with previous similar studiers: A high percentage of anthracosis and viral cytopathic effects, and a lower percentage of microthrombotic vascular lung injuries, suggesting some probable differences in pathologic events among different populations.

A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated dermatologic disorders

“…With the emerging knowledge of the adverse events following COVID‐19 immunization, an arising demand has been put on clinicians to be updated on the various mild to severe or potentially life‐ threatening manifestations of COVID vaccines, and whether or not certain patient groups can be vaccinated, or what precautions are to be taken with regard to their medical status. Much attention has been focused on hot topics regarding COVID‐19 prognostic and therapeutic options during the pandemic, with special focus on dermatologic concerns, 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 and now with the wide distribution of the COVID vaccines, a comprehensive assessment of the mucocutaneous eruptions associated with COVID‐19 immunization is an issue of great importance, so that with concrete knowledge, vaccination is not hindered by hesitancy through false beliefs about the extension or prevalence of adverse events or worries of flare‐ups or inefficient immunization, and that critical or potentially fatal adverse reactions are safely avoided.…”

“…The authors of this study have worked on various clinical aspects of COVID‐19, COVID‐19 vaccination and dermatology 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 140 , 141 and it seems that this hot topic could answer some questions and concerns about the most encountered specific disorder in the field of dermatology.…”

Erythrodermic flare‐up of psoriasis with COVID‐19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID‐19 on each other along with the special challenges of the pandemic

“… 18 , 19 We have discussed in our previous studies about the potential association between COVID‐19 and dermatology conditions. 6 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 …”

“…Using glucocorticoids is one of the main therapeutic strategies in patients with severe COVID‐19 symptoms; in psoriatic patients, the administration of glucocorticoids during the course of COVID‐19 infection might affect the patient's psoriasis presentation, as in some cases early after the administration of steroids, psoriatic lesions seem to be mitigated, and after finishing the course of treatment, some patients have reported to experience certain degrees of psoriasis flare‐up. 6 , 19 , 20 , 21 , 22 , 25 , 26 , 27 , 28 , 29 , 30 , 31 …”

COVID‐19 and COVID‐19 vaccine‐related dermatological reactions: An interesting case series with a narrative review of the potential critical and non‐critical mucocutaneous adverse effects related to virus, therapy, and the vaccination

“…7,9 The authors of this study have worked on several aspects of COVID-19 including reviews regarding various dermatologic and prognostic concerns in this global calamity. 9,[29][30][31][32][33][34][35][36] This article aimed to yield a comprehensive review and some brief points on common mucocutaneous manifestations of the COVID-19 disease, treatment, and vaccine-related dermatologic adverse events, and finally, the disease pattern in patients with underlying dermatologic conditions in the context of SARS-CoV-2 infection.…”